Description
This episode was released in February 2021, and is being re-shared to offer the research behind the popular weight loss drugs Ozempic and Wegovy. Northwestern's Robert Kushner, MD, discusses the drug semaglutide, typically prescribed for treatment of Type 2 diabetes and the results of the phase 3 clinical trial as a treatment for obesity with very promising results. The study was published in the New England Journal of Medicine, and in 2022, Kushner was awarded the prestigious Herbert Pardes Clinical Research Excellence Award from the Clinical Research Forum.
Understanding the systemic drivers of health disparities within marginalized populations is complex. In this episode, Michelle Birkett, PhD, explains how she uses network and quantitative methodologies to study the health of marginalized populations, particularly sexual and gender minority youth....
Published 11/21/24
Nearly one million people in the U.S. are living with Parkinson's disease, a condition for which there is still no known cause or cure. Joseph Mazzulli, PhD, has led two recent studies published in Neuron and Nature Communications uncovering previously unknown cellular mechanisms driving the...
Published 11/04/24